Investigational drug · Phase 2
VAX-24
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumococcal Vaccines.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "VAX-24"
First trial start
2023
Mar 29, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VAX-24", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Vaccines
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VAX-24" as an intervention, largest first.
- Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in AdultsPivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT05266456 · 835 participants · Start Feb 22, 2022 · Primary completion Jan 10, 2023
Drug: 24 valent pneumococcal conjugate vaccine; 20 valent pneumococcal conjugate vaccine · For: Pneumococcal Vaccines
Sites: Hollywood, Florida; Sunrise, Florida; Savannah, Georgia · 13 sites in all
- Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsPivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT05844423 · 802 participants · Start Mar 29, 2023 · Primary completion Aug 25, 2025
Drug: 0.5 ml dose of 1.1 mcg VAX-24; 0.5 ml dose of PCV20 and 2 more · For: Pneumococcal Vaccines
Sites: Jonesboro, Arkansas; Madera, California; Tampa, Florida · 32 sites in all
- Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsPivotal-lookingCompleted
Vaxcyte, Inc.Industry
NCT05297578 · 207 participants · Start Jun 15, 2022 · Primary completion Feb 15, 2023
Drug: 24-Valent Pneumococcal Conjugate Vaccine; Pneumococcal 20-valent Conjugate Vaccine · For: Pneumococcal Vaccines
Sites: Birmingham, Alabama; DeLand, Florida; Hollywood, Florida · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
Wassil J, Sisti M, Fairman J, et al. · Vaccine 2024
- Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
Wassil J, Sisti M, Fairman J, et al. · Lancet Infect Dis 2024
- Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
Fairman J, Agarwal P, Barbanel S, et al. · Vaccine 2021
Also in development for Pneumococcal Vaccines
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.